Pain
Conditions
Brief summary
The enrolled subjects will get an intravenous cannulation in both elbows. The subject will get before xylocaine spray is placed, the intervention-arm, one intravenous cannulation in one of the elbows, the other intravenous cannulation is placed in the other arm before placebo spray is placed, the control arm. The pain score during insertion of the cannulation, the incidence of adverse events and the success rate and degree of difficulty to place an intravenous cannulation. The subjects and the one who place the cannulations will be blinded to the treatment.
Detailed description
The enrolled subjects will get an intravenous cannulation in both elbows. The influence of the left or right-handedness is reduced by randomizing the arms of the subjects in the placebo group or xylocaine group. The subject will get before xylocaine spray is placed, the intervention-arm, one intravenous cannulation in one of the elbows, the other intravenous cannulation is placed in the other arm before placebo spray is placed, the control arm. The pain score during insertion of the cannulation, the incidence of adverse events and the success rate and degree of difficulty to place an intravenous cannulation. The subjects and the one who place the cannulations will be blinded to the treatment.
Interventions
DRUGXylocaine spray
Cutaneous xylocaine spray before intravenous cannulation.
DRUGPlacebo
Cutaneous placebo before intravenous cannulation.
Sponsors
Isala
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Adults (aged 18 or older) * Signing of the informed consent paper
Exclusion criteria
* Allergy for xylocaine * Pregnancy or breast-feeding * Peripheral neuropathy * Analgesics in the last 24 hours * Skin conditions (eczema, psoriasis, infection, or abrasions) * Difficulties in verbal communication * No intravenous access in both elbows possible (eg status after axillary dissection )
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The pain score of the tested subjects during intravenous cannulation | A few seconds after intravenous cannulation | Visual Analogue Scale (VAS) (0 = no pain, 10 = severe pain) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complications or adverse reactions of xylocaine spray or placebo spray | 5 minutes after xylocaine spray or placebo and 15 minutes after cannulation | — |
| Influence of xylocaine spray in successfully placing an IV cannulation | Before intravenous cannulation | Is the cannulation easy or difficult to access on a scale, 0 to 10 (0 = easy, 10 = very difficult, almost impossible). |
| The degree of difficulty in successfully placing an IV cannulation | A few seconds after intravenous cannulation | Indicate in a scale from 10 (0 = easy, 10 = very difficult, almost impossible) or the cannulation was easy or difficult to access |
Outcome results
None listed